NQO1 and metabolic disease: In particular, metabolic diseases such as obesity and spontaneous hypertension were shown to be reversed upon NQO1 enzymatic action using β-lapachone [112, 113], and pathological conditions such as arterial restenosis due to tissue injury and cisplatin-associated nephrotoxicity were also ameliorated by NQO1 enzymatic action using this substrate [11, 114].